N/A
N=50
TetraGraph in Rocuronium Infusions
Surgery
Bottom Line
View on ClinicalTrials.gov: NCT06472284 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Rocuronium Bolus Dose — 0.8 mg/kg
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- TetraGraph (Device)
- Age
- Pediatric, Adult · 0+ yrs
- Sex
- All
- Sponsor
- Joseph D. Tobias
- Primary completion
- Apr 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rocuronium Bolus Dose |
0.8 | — |
| PRIMARY Rocuronium Infusion Dose |
0.48 | — |
| PRIMARY Maximum Dose of Rocuronium |
1; 41; 6 | — |
| SECONDARY Rocuronium Infusion Time |
201.5 | — |
| SECONDARY Rocuronium Rescue Boluses |
26 | — |
| SECONDARY Anesthesia Time |
339 | — |
| SECONDARY Surgical Time |
225 | — |
Summary
This is a prospective, non-blinded study to evaluate rocuronium infusion requirements using the TetraGraph Neuromuscular Transmission Monitor during surgical procedures in patients less than 18 yrs. of age.
Eligibility Criteria
Inclusion Criteria
- Patients less than 18 years of age
- American Society of Anesthesiologists classification (ASA) 1-4
- Patients undergoing a surgical procedure with general anesthesia and requiring the continuous administration of rocuroniuim
Exclusion Criteria
- Patients less than 28 days old
- Patients with history of a progressive or degenerative peripheral neurologic or neuropathic disorder
- Patients undergoing a surgical procedure in which neuromuscular blockade is not required
- Edematous patients
Data sourced from ClinicalTrials.gov (NCT06472284). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.